By Wallace Witkowski and Victor Reklaitis, MarketWatch
SAN FRANCISCO (MarketWatch) -- Cyberonics Inc. shares declined in the extended session Monday after the medical device maker said its appeal of a medical reimbursement decision was denied.
Diverse product portfolio and scale across geographies to drive shareholder value Focused innovation platform to exploit market opportunities and accelerate product development in heart failure, sleep apnea and percutaneous mitral valve to improve patient outcomes
All-stock transaction resulting in pro forma combined equity value of $2.7 billion Transaction expected to enhance revenue growth, drive cash flow generation and be accretive to cash EPS for all shareholders from 2016 MILAN and HOUSTON , Feb.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.